Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aphton Corporation
Results reported from phase I trial with Lewis Y antibody IGN311
August 10th, 2005
Aphton Corporation (APHT) announced the positive results from an open-label dose-escalating phase I trial with IGN311, a humanized monoclonal antibody targeting the Lewis Y tumor-associated antigen. Lewis Y is a factor known to be over-expressed in up to 90% of epithelial carcinomas, including breast, colon, gastric and pancreatic cancers. IGN311 is being developed as a potential new therapy for the treatment of Lewis Y positive tumors. In this phase I trial, IGN311 demonstrated favorable safety and tolerability, and advantageous pharmacokinetics with a serum half-life of more than 20 days. Data from the trial also indicate efficacy of IGN311 against...
Source: Biotech Week (2005-08-10)
|
